Literature DB >> 29729201

Prurigo Activity Score (PAS): validity and reliability of a new instrument to monitor chronic prurigo.

J Pölking1, C Zeidler1, F Schedel1, N Osada1, M Augustin2, D Metze1, M P Pereira1, G Yosipovitch3, J D Bernhard4, S Ständer1.   

Abstract

BACKGROUND: Currently available tools to monitor patients with chronic prurigo over time focus on pruritus and quality of life parameters, while no instrument objectively assessing the pruriginous lesions is yet available.
OBJECTIVE: The objective of this study was to develop a physician-assessed Prurigo Activity Score (PAS), a new tool to monitor the distribution and activity of chronic prurigo lesions and to evaluate its reliability and validity.
METHODS: The 7-item PAS questionnaire as well as validated pruritus intensity scales (VAS, NRS) and a skin-related quality of life score (DLQI) were completed for 264 patients (172 females, age 61 years) at least twice over a period of 2 years. In addition, a 60-min test-retest reliability test was performed by four experts for a random sample of 12 patients.
RESULTS: The PAS showed good test-retest reliability (Cohens κ > 0.61; Cronbach-alpha > 0.76), ordinal or metric items showed high inter-rater reliability (Kendalls > 0.61) and items recording the number of lesions correlated significantly to each other (P < 0.001). The highest correlation to external constructs was achieved with DLQI. The feasibility test conducted by four raters indicated the suitability of PAS for tracking chronic prurigo in the clinical setting. DISCUSSION: The PAS is a useful tool to objectively monitor pruriginous lesions in chronic prurigo patients over time. The sensitivity of change in the PAS score should be analysed in future studies.
© 2018 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2018        PMID: 29729201     DOI: 10.1111/jdv.15040

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  4 in total

1.  Abnormal Plasma Levels of Steroids and Their Ratios in Patients With Prurigo Nodularis: A Pilot Study.

Authors:  Liuxi Chu; Xin Shu; Yan Wu; Haoran Yang; Qin Lu; Huihua Deng
Journal:  Front Physiol       Date:  2022-06-28       Impact factor: 4.755

Review 2.  Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.

Authors:  Hideyuki Ujiie; David Rosmarin; Michael P Schön; Sonja Ständer; Katharina Boch; Martin Metz; Marcus Maurer; Diamant Thaci; Enno Schmidt; Connor Cole; Kyle T Amber; Dario Didona; Michael Hertl; Andreas Recke; Hanna Graßhoff; Alexander Hackel; Anja Schumann; Gabriela Riemekasten; Katja Bieber; Gant Sprow; Joshua Dan; Detlef Zillikens; Tanya Sezin; Angela M Christiano; Kerstin Wolk; Robert Sabat; Khalaf Kridin; Victoria P Werth; Ralf J Ludwig
Journal:  Front Med (Lausanne)       Date:  2022-06-09

3.  Investigator's Global Assessment of Chronic Prurigo: A New Instrument for Use in Clinical Trials.

Authors:  Claudia Zeidler; Manuel P Pereira; Matthias Augustin; Mary Spellman; Sonja Ständer
Journal:  Acta Derm Venereol       Date:  2021-02-17       Impact factor: 3.875

Review 4.  Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments.

Authors:  Anthony Bewley; Bernard Homey; Andrew Pink
Journal:  Dermatol Ther (Heidelb)       Date:  2022-08-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.